WealthShield Partners’s ChemoCentryx, Inc. CCXI Stock Holding History

WealthShield Partners’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,676	Closed	-$291K	–	1217
2021 Q1	$291K	Buy	5,676 +2,137	+60%	+$129K	0.05%	210
2020 Q4	$219K	Buy	+3,539	New	+$203K	0.04%	276
2020 Q3	–	Sell	-4,047	Closed	-$233K	–	405
2020 Q2	$233K	Buy	+4,047	New	+$220K	0.11%	182

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WealthShield Partners's CCXI Position: Q2 2021 in Review

WealthShield Partners sold out of ChemoCentryx, Inc. (CCXI) in Q2 2021, closing a stake of 5,676 shares — an estimated $291K sold.

WealthShield Partners first reported a position in CCXI in Q2 2020 and held it in 3 quarters. The position peaked at $291K in Q1 2021. 146 funds tracked by Wall St. Rank hold CCXI as of Q2 2021.

WealthShield Partners reported no remaining ChemoCentryx, Inc. position as of Q2 2021 after selling out during the quarter.
WealthShield Partners sold 5,676 ChemoCentryx, Inc. shares in Q2 2021, an estimated $291K.
WealthShield Partners first reported a position in ChemoCentryx, Inc. in Q2 2020 and held it in 3 quarters.
WealthShield Partners's ChemoCentryx, Inc. position peaked at $291K in Q1 2021.
146 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2021.

Based on WealthShield Partners's 13F filing for Q2 2021, filed 6 Aug 2021.